Belite Bio, Inc (NASDAQ: BLTE) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
170.35
+1.14+0.67%
News
Up 0.7% — Belite Bio, Inc. Sponsored ADR $BLTE Shares Sold by Squarepoint Ops LLC (defenseworld.net).
Medium confidence
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 2.54% | Shs Outstand | 40.09M | Perf Week | -2.70% |
| Market Cap | 6.83B | Forward P/E | 89.66 | EPS next Y | 1.90 | Insider Trans | -21.77% | Shs Float | 18.47M | Perf Month | 4.79% |
| Enterprise Value | 6.74B | PEG | - | EPS next Q | -0.79 | Inst Own | - | Short Float | 2.62% | Perf Quarter | 14.84% |
| Income | -78.00M | P/S | 0.00 | EPS this Y | - | Inst Trans | - | Short Ratio | 5.42 | Perf Half Y | 5.58% |
| Sales | 0.00 | P/B | 75.87 | EPS next Y | 159.75% | ROA | -12.93% | Short Interest | 1.05M | Perf YTD | 6.50% |
| Book/sh | 2.25 | P/C | 77.60 | EPS next 5Y | - | ROE | -15.65% | 52W High | 200.01 -14.83% | Perf Year | 154.63% |
| Cash/sh | 2.20 | P/FCF | - | EPS past 3/5Y | - | ROIC | -15.28% | 52W Low | 67.82 151.18% | Perf 3Y | 464.07% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 3.65% 4.49% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | -75.42% | Oper. Margin | 0.00% | ATR (14) | 7.84 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 33.56 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 52.16 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 33.56 | EPS Q/Q | -40.00% | SMA20 | 1.59% | Beta | 0.93 | Target Price | 245.83 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | - | SMA50 | 5.06% | Rel Volume | 0.53 | Prev Close | 169.21 |
| Employees | 41 | LT Debt/Eq | 0.01 | Earnings | Nov 09 | SMA200 | 6.54% | Avg Volume | 195.58K | Price | 170.35 |
| IPO Date | Apr 29, 2022 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 9.88% - | Net Debt/EBITDA | 0.00 | Volume | 104,224 | Change | 0.67% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-09-26 | Reiterated | Mizuho | Outperform | $220 → $234 |
| Sep-08-26 | Reiterated | HC Wainwright & Co. | Buy | $214 → $245 |
| Sep-04-26 | Initiated | Canaccord | Buy | $303 |
| Aug-14-26 | Reiterated | Mizuho Securities | Outperform | $215 → $220 |
| Aug-14-26 | Reiterated | Cantor Fitzgerald | Overweight | $270 |
| Aug-14-26 | Reiterated | Morgan Stanley | Overweight | $191 → $206 |
| Aug-12-26 | Reiterated | HC Wainwright & Co. | Buy | $200 → $214 |
| May-26-26 | Reiterated | Mizuho | Outperform | $223 → $215 |
| May-22-26 | Reiterated | Truist Financial | $217 | |
| Mar-03-26 | Reiterated | Needham | $217 |
Latest News· Times ET
Today
Sep-14-26
Sep-14-2609:51AM
Sep-09-26
Sep-09-2606:55AM
Sep-08-26
Sep-08-2602:00AM
Sep-04-26
Sep-02-26
Sep-02-2608:02PM
05:31PM
11:44AM
Sep-01-26
Aug-24-26
Aug-21-26
Aug-21-2604:00AM
Aug-14-26
Aug-14-2610:03AM
Aug-13-26
Company
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | |
|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | — | — | — | |
| Gross Profit | 0 | 0 | 0 | — | — | — | |
| Selling, General and Administrative Excl. Other | 39 | 10 | 7 | — | — | — | |
| Research and Development | 45 | 30 | 25 | — | — | — | |
| Other Operating Expense | 0 | 0 | 0 | — | — | — | |
| Operating Income | -84 | -40 | -32 | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 7 | 4 | 0 | — | — | — | |
| Net Income Before Taxes | -78 | -36 | -32 | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | |
| Consolidated Net Income | -78 | -36 | -32 | — | — | — | |
| Net Income From Continuing Operations | -78 | -36 | -32 | — | — | — | |
| Net Income | -78 | -36 | -32 | — | — | — | |
| EPS (Recurring) | -2.31 | -1.18 | -1.19 | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -2.31 | -1.18 | -1.19 | — | — | — | |
| EPS (Diluted) | -2.31 | -1.18 | -1.19 | — | — | — | |
| EBITDA | -77 | -36 | -31 | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | |
| Shares Outstanding | 34 | 31 | 27 | — | — | — | |
| Market Capitalization | 5,439 | 1,956 | 1,235 | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Lin Yu-Hsin | Chief Executive Officer | Sep 08 '26 | Sale | 196.56 | 26,000 | 5,110,486 | 70,134 | Sep 09 |
| Chuang Hao-Yuan | Chief Financial Officer | Sep 08 '26 | Sale | 196.42 | 17,962 | 3,528,139 | 26,038 | Sep 09 |
| Lin Yu-Hsin | Chief Executive Officer | Sep 04 '26 | Sale | 187.71 | 74,435 | 13,972,062 | 96,134 | Sep 09 |
| Chuang Hao-Yuan | Chief Financial Officer | Sep 04 '26 | Sale | 187.64 | 49,433 | 9,275,391 | 44,000 | Sep 09 |
| Chuang Hao-Yuan | Chief Financial Officer | Aug 12 '26 | Sale | 180.35 | 367 | 66,187 | 93,433 | Aug 14 |
| Lin Yu-Hsin | Chief Executive Officer | Aug 12 '26 | Sale | 180.35 | 365 | 65,827 | 170,569 | Aug 14 |
| Scholl Hendrik Peter | Chief Medical Officer | Jun 18 '26 | Sale | 145.24 | 10,000 | 1,452,436 | 15,000 | Jun 22 |
| Scholl Hendrik Peter | Chief Medical Officer | Jun 16 '26 | Sale | 140.57 | 10,000 | 1,405,729 | 25,000 | Jun 17 |
| MATA NATHAN L. | Chief Scientific Officer | May 07 '26 | Sale | 153.21 | 666 | 102,039 | 0 | May 08 |
| MATA NATHAN L. | Chief Scientific Officer | May 06 '26 | Sale | 153.84 | 1,000 | 153,840 | 666 | May 07 |
| MATA NATHAN L. | Chief Scientific Officer | May 05 '26 | Sale | 155.50 | 1,000 | 155,503 | 1,666 | May 06 |
| MATA NATHAN L. | Chief Scientific Officer | May 04 '26 | Sale | 155.64 | 1,000 | 155,635 | 2,666 | May 05 |
| MATA NATHAN L. | Chief Scientific Officer | May 01 '26 | Sale | 155.78 | 1,000 | 155,778 | 3,666 | May 04 |
| MATA NATHAN L. | Chief Scientific Officer | Apr 30 '26 | Sale | 156.97 | 1,000 | 156,972 | 4,666 | May 01 |
| MATA NATHAN L. | Chief Scientific Officer | Apr 29 '26 | Sale | 155.82 | 1,000 | 155,816 | 5,666 | Apr 30 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.